Life science and healthcare funds are undervalued

Mike Kelly, managing director of Hamilton Lane, notes that thanks to a flurry of exits, life sciences is no longer being beaten down by LPs

1 January 2014•4 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.